The impact of deleting 5 personality disorders in the new DSM-5

 

Rhode Island Hospital study finds changes could result in false-negative diagnoses

 

Providence, R.I., USA (January 24, 2012) – A newly published paper from Rhode Island Hospital reports on the impact to patients if five personality disorders are removed from the upcoming revision to the Diagnostic and Statistical Manual, 5th edition (DSM-5). Based on their study, the researchers believe these changes could result in false-negative diagnoses for patients. The paper is published in the Journal of Clinical Psychiatry and is now available online in advance of print.

 

The DSM-5 Personality and Personality Disorders work group made several recommendations to change the approach toward diagnosing personality disorders. One of those recommendations is to delete five personality disorders as a way to reduce the level of comorbidity among the disorders. The ones originally slated to be removed include paranoid, schizoid, histrionic, narcissistic and dependent personality disorders. More recently, the Work Group recommended that narcissistic be retained. Lead author Mark Zimmerman, M.D., director of outpatient psychiatry at Rhode Island Hospital, points out, however, that no data were cited describing the impact this deletion had, or might have, on the overall prevalence of personality disorders. Likewise, no research was cited for the Work Group’s reversal in deciding to retain narcissistic personality disorder.

 

"When it comes to revising the official diagnostic classification system, the guiding principle should be that criteria should not be changed in the absence of research demonstrating that the new approach is superior to the old in either validity or clinical utility, preferably both," Zimmerman states. "Despite assurances that only data-driven modification would be made, with each new edition of the DSM, we have witnessed repeated instances of changes being made in the absence of sufficient data demonstrating the new criteria is superior."

 

To evaluate the proposed changes of deleting five personality disorders from the DSM-5, Zimmerman and his colleagues evaluated 2,150 psychiatric outpatients, more than one-quarter of whom were diagnosed with one of the 10 DSM-IV personality disorders. When removing the proposed deleted disorders, 59 patients who were diagnosed with a personality disorder according to the DSM-IV criteria would no longer be so diagnosed. Thus, the findings suggest that patients will have false-negative diagnoses based on the proposed revisions to the DSM-IV.

 

Zimmerman comments, "The findings of the present study highlight our concerns about adopting changes in the diagnostic manual without adequate empirical evaluation beforehand. To be sure, there are problems with the classification of personality disorders, however, the identification of a problem is only the first step of a process resulting in a change to diagnostic criteria."

 

He concludes, "The classification of personality disorders would not be improved if the new criteria or diagnostic material were more clinically useful but less reliable and valid."

 

 

Zimmerman’s principal affiliation is Rhode Island Hospital, a member hospital of the Lifespan health system in Rhode Island. The researcher is also an Associate Professor of Psychiatry and Human Behavior at The Warren Alpert Medical School of Brown University. Other researchers involved in the study with Zimmerman include Iwona Chelminski, Ph.D.; Diane Young, Ph.D., Kristy Dalrymple, Ph.D., and Jennifer Martinez, B.A., all of Rhode Island Hospital and Alpert Medical School.

 

 

About Rhode Island Hospital

 

Founded in 1863, Rhode Island Hospital in Providence, R.I., is a private, not-for-profit hospital and is the largest teaching hospital of The Warren Alpert Medical School of Brown University. A major trauma center for southeastern New England, the hospital is dedicated to being on the cutting edge of medicine and research. Rhode Island Hospital received more than $55 million last year in external research funding. For more information on Rhode Island Hospital, visit www.rhodeislandhospital.org, follow us on Twitter @RIHospital or like us on Facebook www.facebook.com/rhodeislandhospitalpage

 

 


Lifespan, 24.01.2012 (tB).

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen
Meilenstein in der Krebsversorgung am UKW: 100ste Patient erhält CAR-T-Zelltherapie

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…